SUPERNUS PHARMACEUTICALS, INC. Cash and Restricted Cash
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Cash and Restricted Cash of $181.40 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-03
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $181.40M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $186.32M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $129.90M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $152.82M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $181.40M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $186.32M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $129.90M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $152.82M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $144.71M 10-Q · filed 2026-08-03 |
| 2025-03-31 | $115.85M 10-Q · filed 2026-05-05 |
| 2024-12-31 | $69.33M 10-Q · filed 2026-08-03 |
| 2024-09-30 | $31.67M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $52.09M 10-Q · filed 2025-08-05 |
| 2024-03-31 | $63.40M 10-Q · filed 2025-05-06 |
| 2023-12-31 | $75.05M 10-K · filed 2026-03-02 |
| 2023-09-30 | $94.98M 10-Q · filed 2024-11-04 |
| 2023-06-30 | $24.71M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $462.20M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $93.12M 10-K · filed 2026-03-02 |
| 2022-09-30 | $111.49M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $173.43M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $115.72M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $203.43M 10-K · filed 2025-02-25 |
| 2021-09-30 | $215.28M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $223.77M 10-Q · filed 2022-08-08 |
| 2021-03-31 | $255.64M 10-Q · filed 2022-05-12 |
| 2020-12-31 | $288.64M 10-K · filed 2023-03-09 |
| 2020-09-30 | $204.29M 10-Q · filed 2021-11-05 |
| 2020-06-30 | $210.97M 10-Q · filed 2021-08-06 |
| 2020-03-31 | $225.77M 10-Q · filed 2021-05-07 |
| 2019-12-31 | $181.38M 10-K · filed 2023-03-09 |
| 2019-09-30 | $116.89M 10-Q · filed 2020-11-06 |
| 2019-06-30 | $87.34M 10-Q · filed 2020-08-17 |
| 2019-03-31 | $122.78M 10-Q · filed 2020-05-15 |
| 2018-12-31 | $192.25M 10-K · filed 2022-04-13 |
| 2018-09-30 | $123.82M 10-Q · filed 2019-11-08 |
| 2018-06-30 | $35.20M 10-Q · filed 2019-08-09 |
| 2018-03-31 | $444.14M 10-Q · filed 2019-05-10 |
| 2017-12-31 | $100.30M 10-K · filed 2021-03-08 |
| 2017-09-30 | $81.92M 10-Q · filed 2018-11-09 |
| 2017-06-30 | $61.74M 10-Q · filed 2018-08-09 |
| 2017-03-31 | $59.60M 10-Q · filed 2018-05-10 |
| 2016-12-31 | $66.40M 10-K · filed 2020-02-28 |
| 2015-12-31 | $33.50M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |